MicrosoftExpanded

Roche modernizes breast cancer diagnostics with Azure-based AI

Use case typeMedical imagingUpdated Jun 13, 2026

Roche has deployed artificial intelligence solutions such as uPath Ki-67, ER, and PR digital pathology algorithms to automate tumor marker analyses. Integrated with Roche's uPath NAVIFY platform, these tools enhance diagnostic precision while reducing manual workload for breast cancer pathologists.

Organization
Roche
Industry
Healthcare
Published
December 2021

Reported outcomes

Strategic outcomes

New product / capabilityAutomated tumor marker analysisBetter decisions & insightImproved diagnostic precisionCustomer experience & trustHigher diagnostic consistencyEmployee experienceReduced manual workload

Primary read

Use case focus

Showing 2 of 2

  • 1AI-enhanced pathology analysis
  • 2Cancer diagnostic automation
  • Manual complexity in tumor marker analysis
  • Need for higher diagnostic precision
  • Long turnaround time in pathology reports
  • Integration of AI-based uPath Ki-67, ER, and PR algorithms
  • Utilization of Azure-based NAVIFY Digital Pathology platform
  • Deep learning for analyzing whole-slide imaging
Technologies
  • Faster tumor marker analysis
  • Higher diagnostic consistency
  • Enhanced pathologist confidence due to AI integration
Architecture

Pathology imaging is analyzed using Azure AI and deep learning models via Roche's uPath NAVIFY platform.

Sources & evidence1
ExpandedExpanded

The same organization appears in newer AI deployment evidence.

  • Same organization re-documented as recently as 2025.
  • Cited source last checked Jun 12, 2026 — ok (0/1 broken).

Measures whether this deployment's public evidence persists — not whether the system is still in production.

Groundedness: Unavailable

AI-generated summary. Verify important details with the linked sources before relying on this case.

Explore related AI use cases
This website uses cookies to enhance the user experience. Learn more.